Reminder for Diabetes, Gestational

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Diabetes, Gestational+1 More
Reminder - Behavioral
Eligibility
18 - 65
Female
What conditions do you have?
Select

Study Summary

This trial looked at whether a reminder system for postpartum diabetes screening would be effective in women who had gestational diabetes.

Eligible Conditions
  • Diabetes, Gestational

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Diabetes, Gestational

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 1 year

1 year
Postpartum Diabetes screening in GDM patients

Trial Safety

Safety Progress

1 of 3

Other trials for Diabetes, Gestational

Trial Design

2 Treatment Groups

Routine care
1 of 2
active management
1 of 2
Active Control
Experimental Treatment

78 Total Participants · 2 Treatment Groups

Primary Treatment: Reminder · No Placebo Group · N/A

active management
Behavioral
Experimental Group · 1 Intervention: Reminder · Intervention Types: Behavioral
Routine careNoIntervention Group · 1 Intervention: Routine care · Intervention Types:
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Reminder
2014
N/A
~207520

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor
398 Previous Clinical Trials
131,070 Total Patients Enrolled
1 Trials studying Diabetes, Gestational
284 Patients Enrolled for Diabetes, Gestational

Eligibility Criteria

Age 18 - 65 · Female Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: October 29th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.